Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view
Author:
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
http://link.springer.com/content/pdf/10.1007/s12020-014-0523-4.pdf
Reference34 articles.
1. E.L. Mazzaferri, R.T. Kloos, Clinical review 128: current approaches to primary therapy forpapillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 86(4), 1447–1463 (2001)
2. Y.D. Podnos, D.D. Smith, L.D. Wagman, J.D. Ellenhorn, Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J. Surg. Oncol. 96(1), 3–7 (2007)
3. Sureveillance, Epidemiology, and End Results Program Cancer Stat Facts. http://seer.cancer.gov/ . Accessed 1 Sept 2014
4. American Thyroid Association (ATA), Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009)
5. G.W. Randolph, Q.Y. Duh, K.S. Heller, V.A. LiVolsi, S.J. Mandel, D.L. Steward, R.P. Tufano, R.M. Tuttle, American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal Surgery, The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 22(11), 1144–1152 (2012)
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors;Endocrine Practice;2023-11
2. Factors Affecting Ablation Success After I-131 Radioactive Iodine Therapy in Low and Intermediate Risk Papillary Thyroid Cancer;Hormone and Metabolic Research;2023-06-02
3. Current Controversies in Low-Risk Differentiated Thyroid Cancer: Reducing Overtreatment in an Era of Overdiagnosis;The Journal of Clinical Endocrinology & Metabolism;2022-11-04
4. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer;International Journal of Molecular Sciences;2022-05-20
5. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer;Expert Opinion on Investigational Drugs;2021-09-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3